Abstract:DNA damage repair (DDR) comprises the detection and correction of alterations in the chemical structure of DNA. The dysfunction of the DDR process has been determined to have important implications for tumor carcinogenesis, malignancy progression, treatment resistance, and prognosis assessment. However, the role of the DDR process in gastric cancer (GC) remains to be fully understood. Thus, a total of 2,019 GC samples from our hospital (Harbin Medical University Cancer Hospital in china) and 12 public data sets were included in our study. In this study, single-sample gene set enrichment analysis (ssGSEA) was used to generate the DDR pathway activity profiles of 8 DDR sub-pathways and identify a DDR pathway signature by combining the DDR sub-pathway gene sets. The DDR pathway profiling’s impacts on the clinical outcomes, biological functions, genetic variants, immune heterogeneity, and treatment responses were analyzed through multidimensional genomics and clinical data. The results demonstrate that the DDR pathway profiling was clearly distinguished between tumor and normal tissues. The DDR pathway profiling reveals patient-level variations, which may contribute to explaining the high heterogeneity of human GC for the biological features and treatment outcomes. Thus, tumors with low DDR signature scores were independently correlated with shorter overall survival time and significantly associated with mesenchymal, invasion, and metastasis phenotypes. The statistical model integrating this DDR pathway signature with other clinical predictors outperforms each predictor alone for predicting overall survival in discrimination, calibration, and net clinical benefit. Moreover, low DDR signature scores were tightly associated with genome stability, characterized by low tumor mutational burden (TMB) and low fractions of genome alteration. Furthermore, this study confirms that patients with low DDR pathway signature scores might not benefit from adjuvant chemotherapy and a monoclonal antibody directed against programmed cell death-1 ligand 1 (anti-PD1) therapy. These findings highlighted that the DDR pathway profiling confers important implications for patients with GC and provides insights into the specific clinical and molecular features underlying the DDR process, which may help to facilitate clinical management.

DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF‐1α Ubiquitination and Degradation

The Keratin 17/YAP/IL6 Axis Contributes to E-cadherin Loss and Aggressiveness of Diffuse Gastric Cancer

Zic1 Suppresses Gastric Cancer Metastasis by Regulating Wnt/β‐catenin Signaling and Epithelial‐mesenchymal Transition

Discoidin domain receptor 1 is a potential target correlated with tumor invasion and immune infiltration in gastric cancer

Wd40 Repeat-Containing 62 Overexpression As A Novel Indicator of Poor Prognosis for Human Gastric Cancer

CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.

Significant association of DIRC1 overexpression with tumor progression and poor prognosis in gastric cancer.

HKDC1 upregulation promotes glycolysis, disease progression and confers chemoresistance onto gastric cancer

Loss of DRD5P2 in hypoxia attenuates ROCK2 degradation to promote EMT and gastric cancer metastasis

Discoidin Domain Receptor 1 Activity Drives an Aggressive Phenotype in Bladder Cancer.

Intercellular adhesion molecule 2 as a novel prospective tumor suppressor induced by ERG promotes ubiquitination-mediated radixin degradation to inhibit gastric cancer tumorigenicity and metastasis

CTHRC1 promotes gastric cancer metastasis via HIF-1α/CXCR4 signaling pathway

DDR1 Functions As an Immune Negative Factor in Colorectal Cancer by Regulating Tumor‐infiltrating T Cells Through IL‐18

DDR1a Promotes Tumor Invasion and Metastasis Via the ZEB1/COL4 Axis in Bladder Cancer

DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway

Zinc Finger Protein CTCF Regulates Extracellular Matrix (ECM)-Related Gene Expression Associated With the Wnt Signaling Pathway in Gastric Cancer

Interaction between the EPHB2 receptor and EFNB1 ligand drives gastric cancer invasion and metastasis via the Wnt/β-catenin/FAK pathway

Gastrointestinal Factor GDDR Attenuates Epithelial–Mesenchymal Transition in Gastric Cancer Via Inhibiting AKT Signal

Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer

YTHDC1 promotes the malignant progression of gastric cancer by promoting ROD1 translocation to the nucleus

Gliomedin drives gastric cancer cell proliferation and migration, correlating with a poor prognosis